Literature DB >> 19946093

Pitfalls in the radiological and pathological correlation of tumour response rates of hepatocellular carcinoma following radiofrequency ablation.

Y K Cho1, Y Kim, H Rhim.   

Abstract

According to the American Association for the Study of Liver Diseases (AASLD) guidelines, radiofrequency ablation (RFA) is a safe and effective treatment for patients with unresectable hepatocellular carcinoma (HCC). In most studies, the initial complete tumour response rates of small HCCs < or =3 cm following RFA have been reported as more than 90% or 95%, and local tumour progression rates have been reported as approximately 10% or 20%. Notwithstanding these promising clinical outcomes, the complete tumour response rates for HCC following RFA as determined by conventional histopathological diagnostic criteria have been reported to be less than 50% in many recent reports. While considering that most cases of local tumour progression of HCC are known to occur within two years following RFA, it may not be reasonable to assume that clinical and radiological examinations have significantly overestimated the tumour response rates. On the contrary, it is likely that the conventional histopathological examination techniques may have underestimated the tumour response rates. The apparent discrepancy between the histopathological and the radiological tumour response of radiofrequency ablation for hepatocellular carcinomas can be attributed to several histological features, such as thermal fixation or apoptosis, that were not included in the conventional histopathological diagnostic criteria. However, a robust conclusion cannot be derived because of lack of adequate controlled studies, and further well designed prospective multicentre trials will be helpful to solve this issue.

Entities:  

Mesh:

Year:  2009        PMID: 19946093     DOI: 10.1136/jcp.2009.069716

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations.

Authors:  Scott M Thompson; Matthew R Callstrom; Bruce Knudsen; Jill L Anderson; Rickey E Carter; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  J Vasc Interv Radiol       Date:  2012-01-20       Impact factor: 3.464

2.  Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future.

Authors:  Beat M Künzli; Paolo Abitabile; Christoph A Maurer
Journal:  World J Hepatol       Date:  2011-01-27

3.  Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma.

Authors:  Scott M Thompson; Matthew R Callstrom; Bruce E Knudsen; Jill L Anderson; Shari L Sutor; Kim A Butters; Chaincy Kuo; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  Invest Radiol       Date:  2013-06       Impact factor: 6.016

4.  Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers.

Authors:  Reto Bale; Peter Schullian; Gernot Eberle; Daniel Putzer; Heinz Zoller; Stefan Schneeberger; Claudia Manzl; Patrizia Moser; Georg Oberhuber
Journal:  Hepatology       Date:  2019-02-14       Impact factor: 17.425

5.  CT perfusion imaging can detect residual lung tumor early after radiofrequency ablation: a preliminary animal study on both tumoral and peri-tumoral region assessment.

Authors:  Zenghui Cheng; Yixue Wang; Min Yuan; Jianxiao Liang; Yanling Feng; Yuxin Shi; Zhiyong Zhang; Fei Shan
Journal:  J Thorac Dis       Date:  2022-01       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.